Ila M. Saunders, PharmD, BCOP, DipACLM, FHOPA

Articles by Ila M. Saunders, PharmD, BCOP, DipACLM, FHOPA

a vibrant microscopic view of malignant hematologic cells, their structure distorted and disorganized, while GFH009, represented by a glowing pathway | Image Caption: catalin | stock.adobe.com

Efficacy and Safety in CPX-351 vs 7+3 in Adults Younger Than 60 Years With AML-MRC or t-AML

ByVera Pervitsky, PharmD, BCOP, BCPS,Ila M. Saunders, PharmD, BCOP, DipACLM, FHOPA,Mimi Lo, PharmD, BCOP, BCPS,Rebecca Young, PharmD, BCOP,Benjamin Moskoff, PharmD, BCOP,Yunyi Ren, MS,Machelle Wilson, PhD,Brian A. Jonas, MD, PhD, FACP,Marisela Banez, PharmD, BCOP, BCPS,Julie Guglielmo, PharmD, BCOP

CPX-351 shows promise for younger adults with therapy-related AML, offering improved survival post-transplant despite lower initial remission rates.

Latest Updated Articles



    Contact Info

    259 Prospect Plains Rd, Bldg H
    Cranbury, NJ 08512

    609-716-7777

    Pharmacy Times
    Brand Logo

    © 2025 MJH Life Sciences®

    All rights reserved.

    Home
    About Us
    News
    Contact Us